Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-04-25Clinical Trial Update: Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis [Phase 3]
Phase 3 trial update evaluating arbaclofen for spasticity in multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2022-04-25Clinical Trial Update: One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity [Phase 3]
Phase 3 open-label dose-escalation long-term safety study in multiple sclerosis patients with spasticity completed.
-
CLINICAL_TRIALS trial_result · 2022-04-21Clinical Trial Update: BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®) [Phase 3]
Phase 3 trial of laquinimod in relapsing-remitting multiple sclerosis completed; results posted in 2022.
-
FDA approval · 2022-04-15FDA Approved: COPAXONE — Supplemental Application (Teva Neuroscience, Inc.)
FDA approves a supplemental application for COPAXONE (glatiramer acetate) by Teva Neuroscience, expanding the labeling.
-
CLINICAL_TRIALS trial_result · 2022-04-06Clinical Trial Update: Mesenchymal Cells From Autologous Bone Marrow, Administered Intravenously in Patients Diagnosed With Multiple Sclerosis [Phase 1, Phase 2]
Phase 1/2 trial evaluating autologous bone marrow-derived mesenchymal cells given intravenously in patients with multiple sclerosis has comp…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-03-29FDA Approved: PLEGRIDY PEN — Supplemental Application (Biogen Inc.)
The FDA approved Biogen's supplemental application for Plegridy Pen, the autoinjector device for peginterferon beta-1a, for use in treating …
-
CLINICAL_TRIALS trial_result · 2022-03-17Clinical Trial Update: Famciclovir in Multiple Sclerosis [Phase 2]
Phase 2 clinical trial update for famciclovir in multiple sclerosis is ongoing with unknown status.
-
CLINICAL_TRIALS trial_result · 2022-03-09Clinical Trial Update: A Pilot Trial of Remotely-Supervised Transcranial Direct Current Stimulation (RS-tDCS) to Enhance Motor Learning in Progressive Multiple Sclerosis (MS) [NA]
Pilot trial evaluating remotely-supervised transcranial direct current stimulation to enhance motor learning in progressive multiple scleros…
-
FDA approval · 2022-03-01FDA Approved: MAYZENT — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for MAYZENT (siponimod) from Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2022-02-15Clinical Trial Update: Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis [Phase 4]
Phase 4 clinical trial assessing sequential natalizumab and alemtuzumab therapy in relapsing multiple sclerosis has completed with results p…
-
CLINICAL_TRIALS trial_result · 2022-02-11Clinical Trial Update: Virtual Reality (VR) to Improve Quality of Life in Patients Diagnosed With Neurological Disorders [NA]
A completed clinical trial evaluating virtual reality to improve quality of life in patients with neurological conditions, including multipl…
-
FDA approval · 2022-02-10FDA Approved: TECFIDERA — Supplemental Application (Biogen Inc.)
FDA approved a supplemental application for Tecfidera (dimethyl fumarate) from Biogen Inc. This action relates to an additional regulatory s…
-
FDA approval · 2022-02-10FDA Approved: VUMERITY — Supplemental Application (Biogen Inc.)
The FDA approved Biogen's supplemental application for VUMERITY (diroximel fumarate), updating its labeling.
-
FDA approval · 2022-02-04FDA Approved: BACLOFEN — Original Application (Wilshire Pharmaceuticals, Inc.)
The FDA approved an Original Application for baclofen by Wilshire Pharmaceuticals, authorizing its use for treating spasticity.
-
FDA approval · 2022-01-28FDA Approved: COPAXONE — Supplemental Application (Teva Neuroscience, Inc.)
The FDA approved a supplemental application for COPAXONE, a glatiramer acetate product, manufactured by Teva Neuroscience, Inc.
-
FDA approval · 2022-01-25FDA Approved: BACLOFEN — Original Application (Major Pharmaceuticals)
FDA approved a generic baclofen under an Original Application from Major Pharmaceuticals.
-
CLINICAL_TRIALS trial_result · 2022-01-18Clinical Trial Update: A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment [Phase 3]
Phase 3 trial of ADS-5102 in multiple sclerosis patients with walking impairment has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-01-13Clinical Trial Update: A Prospective Biomarker Study in Active SPMS Subjects Treated With Cladribine Tablets [Phase 4]
A Phase 4 prospective biomarker study in active secondary progressive multiple sclerosis patients treated with cladribine tablets.
-
CLINICAL_TRIALS trial_result · 2022-01-11Clinical Trial Update: A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting [Phase 4]
Phase 4 trial update collecting complementary efficacy, safety, and patient-reported outcomes in active relapsing forms of multiple sclerosi…
-
FDA approval · 2021-12-23FDA Approved: TASCENSO ODT — Original Application (Cycle Pharmaceuticals Ltd)
FDA approved TASCENSO ODT (fingolimod lauryl sulfate) through an Original Application by Cycle Pharmaceuticals Ltd for the treatment of mult…
-
CLINICAL_TRIALS trial_result · 2021-12-21Clinical Trial Update: Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment [Phase 3]
Phase 3 trial update on ADS-5102 for walking impairment in multiple sclerosis; results posted after completion.
-
FDA approval · 2021-11-22FDA Approved: LYVISPAH — Original Application (Amneal Pharmaceuticals LLC)
FDA approved LYVISPAH (baclofen) from Amneal Pharmaceuticals LLC as an Original Application. It is indicated for the management of spasticit…
-
CLINICAL_TRIALS trial_result · 2021-11-22Clinical Trial Update: Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis [Phase 2]
Phase 2 trial assessing AVP-923 for central neuropathic pain in multiple sclerosis has completed with posted results.
-
FDA label_change · 2021-11-18FDA Approved: AMPYRA — Supplemental Application (Merz Pharmaceuticals, LLC)
The FDA approved a supplemental application for AMPYRA (dalfampridine) submitted by Merz Pharmaceuticals, LLC. This action updates the exist…
-
CLINICAL_TRIALS trial_result · 2021-11-16Clinical Trial Update: Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI [Phase 4]
Phase IV trial comparing Betaseron versus Copaxone in relapsing forms of multiple sclerosis using triple-dose gadolinium MRI.